Quarterly ResultApr 30, 2026, 10:06 AM
CNMD Q1 Net Income +129% to $13.8M; EPS $0.45
AI Summary
CONMED Corp (CNMD) reported a significant increase in net income for Q1 2026, rising 129.09% to $13.8 million, with diluted EPS reaching $0.45. This occurred despite a slight 1.31% decrease in net sales to $317.0 million. The company also sold certain gastroenterology product lines for $7.0 million, recognizing a $3.9 million gain, and repurchased $37.0 million in common stock. Net cash provided by operating activities, however, decreased significantly by 67.57% to $13.5 million. CONMED plans to secure financing for its $800.0 million convertible notes maturing in June 2027.
Key Highlights
- Net income increased 129.09% to $13.8 million for the three months ended March 31, 2026.
- Diluted EPS rose 136.84% to $0.45 for the three months ended March 31, 2026.
- Net sales decreased 1.31% to $317.0 million for the three months ended March 31, 2026.
- Sold gastroenterology product lines for $7.0 million, recording a $3.9 million gain.
- Repurchased $37.0 million of common stock during the quarter.
- Orthopedic Surgery sales increased 6.78% to $147.7 million.
- General Surgery sales decreased 7.42% to $169.4 million.
- Intends to secure incremental financing for $800.0 million convertible notes due June 2027.